<DOC>
	<DOCNO>NCT01759394</DOCNO>
	<brief_summary>A Randomized , Open-label , Three-period , Partial-replicate Design Study Evaluate Inter- Intrasubject variability Avatrombopag To-be-marketed Formulation Administered Single Doses 40 mg ( dos express avatrombopag , amount free base ) healthy subject Receiving low-fat Meal .</brief_summary>
	<brief_title>A Open-label , Three-period , Partial-replicate Design Study Evaluate Inter- Intrasubject Variability Avatrombopag To-be-marketed Formulation Administered Single Doses 40 mg Healthy Subjects Receiving Low-fat Meal</brief_title>
	<detailed_description />
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Inclusion Criteria Subjects must meet follow criterion include study : 1 . Healthy male female subject ( age 18 55 year inclusive , time informed consent ) 2 . Body mass index ( BMI ) ≥ 18 kg/m2 ≤ 32 kg/m2 Screening 3 . Platelet count 120 x 109/L 300 x 109/L inclusive Screening , Baseline Period 1 , Baseline Period 3 4 . Platelet count upper limit normal Baseline Period 2 5 . Females must lactate pregnant Screening Baseline ( document negative serum betahuman chorionic gonadotropin [ βhCG ] test minimum sensitivity 25 IU/L equivalent unit βhCG ) . A separate baseline assessment require negative screening pregnancy test obtain 72 hour first dose study drug . 6 . All female consider childbearing potential unless postmenopausal ( amenorrheic least 12 consecutive month , appropriate age group , without know suspected cause ) sterilize surgically ( i.e. , bilateral tubal ligation , total hysterectomy , bilateral oophorectomy , surgery least 1 month dose ) . 7 . Females childbearing potential must unprotected sexual intercourse within 30 day study entry must agree use highly effective method contraception ( e.g. , total abstinence , nonhormonalbased intrauterine device , double barrier method [ condom plus spermicide diaphragm plus spermicide ] , nonestrogenbased hormonal therapy , progesteroneonly contraceptive implant/injection , vasectomized partner confirm azoospermia ) throughout entire study period 30 day study drug discontinuation . If currently abstinent , subject must agree use double barrier method describe becomes sexually active study period 30 day study drug discontinuation . The use estrogenbased hormonal contraceptive allow potential increase risk venous thrombosis . All female reproductive potential use estrogencontaining oral contraceptive must discontinue contraceptive product least 30 day dosing , throughout entire study period , 30 day study drug discontinuation , use use aforementioned method . 8 . Male subject must successful vasectomy ( confirm azoospermia ) female partner must meet criterion ( i.e. , childbearing potential practicing highly effective contraception throughout study period 90 day study drug discontinuation ) . No sperm donation allow study period least 90 day last dose study drug . 9 . Provide write informed consent 10 . Willing able comply aspect protocol Exclusion Criteria Subjects meet follow criterion exclude study : 1 . Evidence clinically significant cardiovascular , hepatic , gastrointestinal , renal , respiratory , endocrine , hematologic , neurologic , psychiatric disease abnormality know history gastrointestinal surgery could impact PK study drug 2 . Agents associated thrombotic event ( include oral contraceptive ) require discontinue 30 day prior first study drug administration 3 . Evidence organ dysfunction clinically significant deviation normal medical history , e.g. , history splenectomy 4 . History arterial venous thrombosis , include partial complete thromboses ( e.g. , stroke , transient ischemic attack , myocardial infarction , deep vein thrombosis , pulmonary embolism ) 5 . Known family history hereditary thrombophilic disorder ( e.g. , Factor V Leiden , antithrombin III deficiency , etc . ) 6 . Hemoglobin less low limit normal 7 . Clinically significant illness within 8 week , clinically significant infection within 4 week , dose 8 . Evidence clinically significant deviation normal physical examination , vital sign , clinical laboratory determination Screening Baseline Periods 1 3 9 . A corrected QT interval use Fridericia 's formula ( QTcF ) &gt; 450 m Screening 10 . A known suspected history drug alcohol misuse within 6 month Screening , positive drug test Screening Baseline Periods 1 3 11 . Positive result human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCVAb ) test Screening 12 . Receipt blood product within 4 week , donation blood within 8 week , donation plasma within 1 week dose 13 . Known history clinically significant drug food allergy experience significant seasonal allergy ( e.g. , hay fever ) hypersensitivity avatrombopag and/or excipients 14 . Use prescription drug within 4 week within five time drug 's halflife ( time &gt; 4 week ) Screening 15 . Participation another clinical trial within 60 day dose concurrent enrollment another clinical trial 16 . Unwilling unable abide requirement study 17 . Any condition would make , opinion investigator , unsuitable study , opinion investigator , likely complete study reason 18 . Females pregnant ( positive βhCG test ) breastfeed 19 . Hypersensitivity aspirin 20 . Scheduled surgery invasive procedure study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>